Sparfosic acid

Identification

Name
Sparfosic acid
Accession Number
DB03459  (EXPT02494)
Type
Small Molecule
Groups
Experimental
Description

Sparfosic acid is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom. This substance is known to target aspartate carbamoyltransferase catalytic chain and CAD protein.

Structure
Thumb
Synonyms
  • N-(phosphonacetyl)-L-aspartic acid
  • N-(phosphonoacetyl)-L-aspartic acid
  • N-phosphonacetyl-L-aspartic acid
  • PALA
  • phosphonoacetyl-L-aspartic acid
External IDs
NCI 224131 / NSC-224131
Categories
UNII
78QVZ7RG8L
CAS number
51321-79-0
Weight
Average: 255.1193
Monoisotopic: 255.014402813
Chemical Formula
C6H10NO8P
InChI Key
ZZKNRXZVGOYGJT-VKHMYHEASA-N
InChI
InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/t3-/m0/s1
IUPAC Name
(2S)-2-[(1-hydroxy-2-phosphonoethylidene)amino]butanedioic acid
SMILES
[H][[email protected]@](CC(O)=O)(N=C(O)CP(O)(O)=O)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAspartate carbamoyltransferase catalytic chainNot AvailableShigella flexneri
UCAD proteinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sparfosic acid.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Sparfosic acid.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfosic acid.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sparfosic acid.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sparfosic acid.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sparfosic acid.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Sparfosic acid.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sparfosic acid.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfosic acid.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Sparfosic acid.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Sparfosic acid.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Sparfosic acid.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Sparfosic acid.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfosic acid.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Sparfosic acid.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sparfosic acid.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
39981
PubChem Substance
46507931
ChemSpider
36554
ChEMBL
CHEMBL504802
Therapeutic Targets Database
DNC000976
HET
PAL
PDB Entries
1acm / 1d09 / 1ekx / 1f1b / 1i5o / 1ml4 / 1q95 / 1tth / 1xjw / 3r7l
show 9 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility8.45 mg/mLALOGPS
logP-2.6ALOGPS
logP-2ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)1.68ChemAxon
pKa (Strongest Basic)0.14ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area164.72 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity47.49 m3·mol-1ChemAxon
Polarizability19.87 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9414
Blood Brain Barrier+0.8603
Caco-2 permeable-0.7034
P-glycoprotein substrateNon-substrate0.8445
P-glycoprotein inhibitor INon-inhibitor0.95
P-glycoprotein inhibitor IINon-inhibitor0.9947
Renal organic cation transporterNon-inhibitor0.9721
CYP450 2C9 substrateNon-substrate0.7884
CYP450 2D6 substrateNon-substrate0.8184
CYP450 3A4 substrateNon-substrate0.6647
CYP450 1A2 substrateNon-inhibitor0.8948
CYP450 2C9 inhibitorNon-inhibitor0.9332
CYP450 2D6 inhibitorNon-inhibitor0.9364
CYP450 2C19 inhibitorNon-inhibitor0.9108
CYP450 3A4 inhibitorNon-inhibitor0.9391
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9952
Ames testNon AMES toxic0.6868
CarcinogenicityNon-carcinogens0.8411
BiodegradationReady biodegradable0.8331
Rat acute toxicity2.0339 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9753
hERG inhibition (predictor II)Non-inhibitor0.9733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Aspartic acid and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Organic phosphonic acids / Secondary carboxylic acid amides / Carboxylic acids / Organopnictogen compounds / Organophosphorus compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Aspartic acid or derivatives / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Dicarboxylic acid or derivatives / Fatty acid / Organophosphonic acid / Organophosphonic acid derivative / Carboxamide group / Secondary carboxylic acid amide
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Unknown
General Function
Aspartate carbamoyltransferase activity
Specific Function
Not Available
Gene Name
pyrB
Uniprot ID
P0A789
Uniprot Name
Aspartate carbamoyltransferase catalytic chain
Molecular Weight
34427.02 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
This protein is a "fusion" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase).
Gene Name
CAD
Uniprot ID
P27708
Uniprot Name
CAD protein
Molecular Weight
242981.73 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:28